Associate Professor of Medicine, University of Chicago Medicine
Hematology
Dr. Lucy A. Godley, MD
|
|
Give Review
Lucy A. Godley practices Hematology. She attended Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine has a rank of 19 in research and a 29 in primary care She received 3 awards: "Regional Top Doctor", "Elected Member" and "CMS Meaningful Use Stage 1 Certification". Dr. Lucy A. Godley is a published physician as well. She has 94 publications published. The latest was: Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Lucy A. Godley, MD accepts Medicare.
Publications
- Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues.
- Genomic analysis of germline and somatic variants in familial myelodysplasia/Acute myeloid leukemia.
- Node-pore sensing enables label-free surface-marker profiling of single Cells.
- Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.
- New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine.
- A new family with a germline ANKRD26 mutation and predisposition to Myeloid malignancies.
- DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia.
- A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced Myeloid neoplasia.
- Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis.
- Linking the genetic architecture of cytosine modifications with human complex traits.
- The mechanistic role of DNA methylation in Myeloid leukemogenesis.
- Geriatric assessment to predict survival in older allogeneic hematopoietic Celltransplantation recipients.
- TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.
- The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide.
- On the origin of leukemic species.
- Familial myelodysplastic syndrome/Acute leukemia syndromes: a review and utility for translational investigations.
- Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.
- Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.
- A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory Leukemia and high-risk myelodysplastic syndromes.
- Large conserved domains of low DNA methylation maintained by Dnmt3a.
- Genome-wide variation of Cytosine modifications between European and african populations and the implications for complex traits.
- Recognizing familial myeloid Leukemia in adults.
- Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.
- Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in Cancer.
- Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, Cell invasion, and DNA methylation of human neuroblastoma Cells.
- Perspectives and future directions for epigenetics in hematology.
- Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
- Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced Lymphomagenesis.
- Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/Acute leukemia predisposition syndromes.
- Pharmacogenomics of chemotherapeutic susceptibility and toxicity.
- Influence of related donor age on outcomes after peripheral blood stem Cell transplantation.
- Epigenetic regulation of hypoxic sensing disrupts cardiorespiratory homeostasis.
- Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical Cancer.
- Dnmt3a is essential for hematopoietic stem Cell differentiation.
- Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic Cell transplantation.
- 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging.
- High Dose Cytarabine and Mitoxantrone: An Effective Induction Regimen for High-Risk Acute Myeloid Leukemia (AML).
- DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-Cell differentiation.
- Tet2 loss leads to increased hematopoietic stem cell self-renewal and Myeloid transformation.
- Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic p...
- Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF Expression Ratio and Advanced Stage.
- An integrated genomic approach to the assessment and treatment of Acute myeloid leukemia.
- Gene mutations, epigenetic dysregulation, and personalized therapy in Myeloid neoplasia: are we there yet?
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
- Molecular biology. Preference by exclusion.
- Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine.
- The impact of MYC expression in Lymphoma biology: beyond Burkitt Lymphoma.
- Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
- DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates Lymphomagenesis.
- The next frontier for stem Cell transplantation: finding a donor for all.
- Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with Myelodysplastic syndromes: the alternative dosing for outpatient treatment (...
- High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple Myeloma.
- Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic Cell transplantation.
- Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related Acute myeloid leukemia.
- DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in Breast cancer cells.
- Alterations of 5-hydroxymethylcytosine in human Cancers.
- Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
- A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory Acute leukemia.
- Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic Cell transplantation.
- Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
- Successful autologous stem cell collection in patients with chronic myeloid Leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL express...
- Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced Acute myeloid leukemia and myelodysplastic syndrome.
- TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human Lymphomagenesis.
- Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic Cell transplantation.
- Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
- Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous Leukemia.
- A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and Acute myeloid leukemia.
- Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant Myeloid diseases with a del(5q).
- cDNA cloning and genomic structure of three genes localized to human chromosome band 5q31 encoding potential nuclear proteins.
- Molecular characterization of KLHL3, a human homologue of the Drosophila kelch gene.
- TTID: A novel gene at 5q31 encoding a protein with titin-like features.
- Absence of p53 in a mouse mammary tumor model promotes tumor Cell proliferation without affecting apoptosis.
- The role of p53 loss in genomic instability and tumor progression in a murine mammary Cancer model.
- Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys.
- Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with Cell proliferation.
- Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.
- Defining the steps in a multistep mouse model for mammary carcinogenesis.
- The use of hypomethylating agents in the treatment of hematologic Malignancies.
- Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins.
- HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor?
- Implications of FLT3 mutations in the therapy of Acute myeloid leukemia.
- Cell characterization using a protein-functionalized pore.
- The identification and characterisation of novel KIT transcripts in aggressive Mast cell malignancies and normal CD34+ cells.
- Aberrant RNA splicing and its functional consequences in Cancer cells.
- Deletion of the der(9q) in chronic myeloid Leukemia: the controversy continues.
- Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend Disease r...
- Epigenetic alterations differ in phenotypically distinct human neuroblastoma Cell lines.
- Treatment of therapy-related Myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
- An update on the safety and efficacy of decitabine in the treatment of Myelodysplastic syndromes.
- Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem Cell transplant: reduced clearance at high ...
- Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder.
- T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors...
- Getting to the root of the stem cell in mutated chronic myeloid Leukemia.
Schools
Northwestern University The Feinberg School Of Medicine
University Of Chicago Hosps
University Chicago
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Elected Member
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
Northwestern University Feinberg School of Medicine
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1720141245 | |
| NPPES Provider LastName | GODLEY | |
| NPPES Provider FirstName | LUCY | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 106.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720141245 |
| Last Name Of The Provider | GODLEY |
| First Name Of The Provider | LUCY |
| View All |
Similar Doctors
|
|
Dr. Gini F. Fleming, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin Posadas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey M. Golomb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Stock, MD |
|
|
Dr. Joseph M. Baron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Hannigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne D. Conzen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerome I. Dickstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hedy L. Kindler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd L. Zimmerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard L. Schilsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Ratain, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Everett E. Vokes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Olatoyosi Odenike, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olufunmailyao Olopade, MD |
|
|
Dr. Christopher K. Daugherty, MD
This Doctor is OpenDoctor Recommended.
|